Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2023-02-24 00:00:00 ET · period of report 2023-02-22 · accession 0001104659-23-025377 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-24 | 2023-02-22 | SUPN | Barlow Carrolee | Dir | A - Grant | $0.00 | +3,882 | 13.3K | +41% | $0 |
| D | 2023-02-24 | 2023-02-22 | SUPN | Barlow Carrolee | Dir | D - Sale to Iss | $0.00 | -3,882 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-22 | A | A | 3,882 | $0.00 | 13,315 | D | — | — | |
| 2 | Derivative | Restricted Stock Units | 2023-02-22 | D | D | 3,882 | $0.00 | 0 | D | — · — to — | 3,882 Common Stock | (F1) Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. (F2) These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2023. |